Back to today’s briefing

Story perspectives

Servier Acquires KER-0193 to Target Fragile X Syndrome

9/9/2025

24 2

Summary

Story summary

Les Laboratoires Servier is acquiring KER-0193 from Kaerus Bioscience for up to $450 million.
KER-0193 targets behavioral, sensory, and cognitive deficits, showing promise in preclinical studies.
The FDA has granted Orphan Drug and Rare Pediatric Drug designations for KER-0193.
Servier aims to initiate a Phase 2 clinical trial in the U.S. and Europe in 2026.
Fragile X syndrome, affecting 1 in 7,000 males, currently has no approved treatments.

1 of 1

Story summary

Les Laboratoires Servier is acquiring KER-0193 from Kaerus Bioscience for up to $450 million.
KER-0193 targets behavioral, sensory, and cognitive deficits, showing promise in preclinical studies.
The FDA has granted Orphan Drug and Rare Pediatric Drug designations for KER-0193.
Servier aims to initiate a Phase 2 clinical trial in the U.S. and Europe in 2026.
Fragile X syndrome, affecting 1 in 7,000 males, currently has no approved treatments.